Pluristem to Exhibit and Present at the BIO International Convention
NEW YORK, Jun 16, 2008 (BUSINESS WIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company will be exhibiting and presenting at the BIO International Convention held in San Diego, California, June 17-20, 2008 (Booth #1224). William R. Prather RPh, MD, Pluristem's Senior Vice President of Corporate Development will present on June 18 at 1:40 PM. The title of the presentation is "The Clinical Application of 3D Expanded Placental-derived Mesenchymal Stromal Cells."
An abstract of the presentation is as follows:
Mesenchymal stromal cells (MSCs) have been documented to be of value in the treatment of a variety of degenerative, autoimmune and inflammatory conditions. Traditionally, MSCs have been expanded using a variety of two-dimensional (2D) techniques. However, a recently developed three dimensional (3D) expansion process for these cells has been found to result in a functional and immunological unique MSC. This talk will expand on these properties and the medical conditions they could potentially address.
Mr. Zami Aberman, Pluristem's President & CEO, stated: "We are pleased we are able to showcase Pluristem at the BIO International Convention, present our unique, proprietary 3D expansion process that transforms MSCs into our PLX cells and report on the use of these PLX cells for a variety of indications. We will give animal trial results for PLX-PAD, PLX-BMT, PLX-STROKE, PLX-MS and PLX-IBD that suggest potential value for these products in treating peripheral artery disease (PAD), as an alternative to bone marrow transplantation (BMT), in treating ischemic stroke, multiple sclerosis (MS) and inflammatory bowel disease (IBD)."
About Pluristem
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.
These placental mesenchymal stromal cells (MSCs) are expanded in the Company's proprietary PluriX(TM) 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. Pluristem believes that the resultant PLX (PLacental eXpanded) cells are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and have immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.
Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company's products in development also include PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; PLX-STROKE, targeting ischemic stroke; PLX-MS, targeting Multiple Sclerosis; and PLX-IBD, targeting Inflammatory Bowel Disease (IBD), which includes Crohn's disease and Ulcerative Colitis.
Pluristem has offices in the USA with research and manufacturing facilities in Israel.
See our product animation on YouTube:
youtube.com. |
